vs
QWEST CORP（CTBB）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
QWEST CORP的季度营收约是Royalty Pharma plc的1.8倍（$1.1B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -187.5%，领先221.9%），Royalty Pharma plc同比增速更快（4.8% vs -15.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -8.6%）
奎斯特公司（以CenturyLink QC名义运营）是一家隶属于 lumen Technologies 的地区性贝尔运营公司。其前身为1911年成立的山地电话电报公司，先后更名为山地贝尔、美国西部通讯，2000年改为现名，业务整合了原Malheur Bell、西北贝尔、太平洋西北贝尔的运营资源。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CTBB vs RPRX — 直观对比
营收规模更大
CTBB
是对方的1.8倍
$622.0M
营收增速更快
RPRX
高出19.8%
-15.0%
净利率更高
RPRX
高出221.9%
-187.5%
两年增速更快
RPRX
近两年复合增速
-8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $622.0M |
| 净利润 | $-2.1B | $214.2M |
| 毛利率 | 67.9% | — |
| 营业利润率 | -183.2% | 62.4% |
| 净利率 | -187.5% | 34.4% |
| 营收同比 | -15.0% | 4.8% |
| 净利润同比 | -627.9% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTBBRPRX
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $1.1B | $609.3M | ||
| Q2 25 | $1.1B | $578.7M | ||
| Q1 25 | $1.2B | $568.2M | ||
| Q4 24 | $1.3B | $593.6M | ||
| Q3 24 | $1.3B | $564.7M | ||
| Q2 24 | $1.3B | $537.3M | ||
| Q1 24 | $1.3B | $568.0M |
净利润CTBBRPRX
| Q4 25 | $-2.1B | $214.2M | ||
| Q3 25 | $176.0M | $288.2M | ||
| Q2 25 | $277.0M | $30.2M | ||
| Q1 25 | $284.0M | $238.3M | ||
| Q4 24 | $391.0M | $208.2M | ||
| Q3 24 | $365.0M | $544.0M | ||
| Q2 24 | $378.0M | $102.0M | ||
| Q1 24 | $353.0M | $4.8M |
毛利率CTBBRPRX
| Q4 25 | 67.9% | — | ||
| Q3 25 | 65.3% | — | ||
| Q2 25 | 68.2% | — | ||
| Q1 25 | 69.3% | — | ||
| Q4 24 | 71.2% | — | ||
| Q3 24 | 69.9% | — | ||
| Q2 24 | 71.6% | — | ||
| Q1 24 | 71.9% | — |
营业利润率CTBBRPRX
| Q4 25 | -183.2% | 62.4% | ||
| Q3 25 | 22.3% | 70.1% | ||
| Q2 25 | 33.1% | 36.3% | ||
| Q1 25 | 33.7% | 94.0% | ||
| Q4 24 | 40.7% | 60.9% | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 40.3% | 50.2% | ||
| Q1 24 | 37.6% | -13.0% |
净利率CTBBRPRX
| Q4 25 | -187.5% | 34.4% | ||
| Q3 25 | 16.1% | 47.3% | ||
| Q2 25 | 24.3% | 5.2% | ||
| Q1 25 | 24.7% | 41.9% | ||
| Q4 24 | 30.2% | 35.1% | ||
| Q3 24 | 28.2% | 96.3% | ||
| Q2 24 | 28.7% | 19.0% | ||
| Q1 24 | 26.8% | 0.8% |
每股收益（稀释后）CTBBRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.0M | $618.7M |
| 总债务越低越好 | $1.7B | $9.0B |
| 股东权益账面价值 | $10.9B | $9.7B |
| 总资产 | $15.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CTBBRPRX
| Q4 25 | $39.0M | $618.7M | ||
| Q3 25 | $36.0M | $938.9M | ||
| Q2 25 | $25.0M | $631.9M | ||
| Q1 25 | $40.0M | $1.1B | ||
| Q4 24 | $26.0M | $929.0M | ||
| Q3 24 | $22.0M | $950.1M | ||
| Q2 24 | $18.0M | $1.8B | ||
| Q1 24 | $14.0M | $843.0M |
总债务CTBBRPRX
| Q4 25 | $1.7B | $9.0B | ||
| Q3 25 | $1.7B | $8.9B | ||
| Q2 25 | $1.7B | $8.0B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.7B | $7.6B | ||
| Q3 24 | $1.7B | $7.6B | ||
| Q2 24 | $1.9B | $7.6B | ||
| Q1 24 | $1.9B | $6.1B |
股东权益CTBBRPRX
| Q4 25 | $10.9B | $9.7B | ||
| Q3 25 | $13.0B | $9.6B | ||
| Q2 25 | $12.8B | $9.5B | ||
| Q1 25 | $12.5B | $9.8B | ||
| Q4 24 | $12.2B | $10.3B | ||
| Q3 24 | $11.9B | $10.3B | ||
| Q2 24 | $11.5B | $9.8B | ||
| Q1 24 | $11.1B | $9.9B |
总资产CTBBRPRX
| Q4 25 | $15.8B | $19.6B | ||
| Q3 25 | $17.9B | $19.3B | ||
| Q2 25 | $17.8B | $18.3B | ||
| Q1 25 | $17.6B | $17.6B | ||
| Q4 24 | $17.4B | $18.2B | ||
| Q3 24 | $17.0B | $18.0B | ||
| Q2 24 | $16.6B | $17.7B | ||
| Q1 24 | $16.4B | $16.1B |
负债/权益比CTBBRPRX
| Q4 25 | 0.15× | 0.92× | ||
| Q3 25 | 0.13× | 0.93× | ||
| Q2 25 | 0.13× | 0.84× | ||
| Q1 25 | 0.13× | 0.78× | ||
| Q4 24 | 0.14× | 0.74× | ||
| Q3 24 | 0.14× | 0.74× | ||
| Q2 24 | 0.17× | 0.78× | ||
| Q1 24 | 0.17× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $402.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $160.0M | — |
| 自由现金流率自由现金流/营收 | 14.5% | — |
| 资本支出强度资本支出/营收 | 22.0% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $938.0M | — |
8季度趋势，按日历期对齐
经营现金流CTBBRPRX
| Q4 25 | $402.0M | $827.1M | ||
| Q3 25 | $427.0M | $702.6M | ||
| Q2 25 | $480.0M | $364.0M | ||
| Q1 25 | $453.0M | $596.1M | ||
| Q4 24 | $548.0M | $742.5M | ||
| Q3 24 | $627.0M | $703.6M | ||
| Q2 24 | $548.0M | $658.2M | ||
| Q1 24 | $471.0M | $664.6M |
自由现金流CTBBRPRX
| Q4 25 | $160.0M | — | ||
| Q3 25 | $252.0M | — | ||
| Q2 25 | $276.0M | — | ||
| Q1 25 | $250.0M | — | ||
| Q4 24 | $277.0M | — | ||
| Q3 24 | $396.0M | — | ||
| Q2 24 | $280.0M | — | ||
| Q1 24 | $194.0M | — |
自由现金流率CTBBRPRX
| Q4 25 | 14.5% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.7% | — | ||
| Q4 24 | 21.4% | — | ||
| Q3 24 | 30.6% | — | ||
| Q2 24 | 21.3% | — | ||
| Q1 24 | 14.7% | — |
资本支出强度CTBBRPRX
| Q4 25 | 22.0% | — | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | 17.9% | — | ||
| Q1 25 | 17.6% | — | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 20.4% | — | ||
| Q1 24 | 21.0% | — |
现金转化率CTBBRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 2.43× | 2.44× | ||
| Q2 25 | 1.73× | 12.06× | ||
| Q1 25 | 1.60× | 2.50× | ||
| Q4 24 | 1.40× | 3.57× | ||
| Q3 24 | 1.72× | 1.29× | ||
| Q2 24 | 1.45× | 6.45× | ||
| Q1 24 | 1.33× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTBB
| Nonrelated Party | $665.0M | 60% |
| Other | $436.0M | 40% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
